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Fluorinated highly functionalized cispentacin derivatives were synthetised starting from an
unsaturated bicyclic b-lactam through C¼C bond functionalization via the dipolar cycloaddition of a
nitrile oxide, isoxazoline opening, and fluorination by OH/F exchange.
Introduction. – As a result of their biological potential, cyclic b-amino acids are of
considerable importance in medicinal chemistry. As conformationally restricted
derivatives, they are building blocks for the construction of biologically active peptides
[1] [2]. They include cispentacin (1), an important potent antifungal [1a] [1b].
Multisubstituted aminocyclopentanecarboxylic acids such as Peramivir (2) and related
analogs 3 (R1¼H, OH; R2¼Et, Pr) exhibit strong antiviral properties [3].
Fluorinated a- and acyclic b-amino acids comprise an expanding area of research,
with increasing impact in both chemistry and biochemistry. They are valuable in
medicinal chemistry as enzyme inhibitors, antitumour agents, or antibiotics [4] [5].
Only a small number of fluorinated cyclic b-amino acids have been prepared so far, this
being particularly true for the five-membered derivatives [6].
We recently reported the synthesis of highly functionalized cispentacin stereo-
isomers 7 and 8 from bicyclic b-lactam 4 by means of the regio- and stereoselective 1,3-
dipolar cycloaddition of a nitrile oxide (acetonitrile N-oxide) to ethyl cis- and trans-2-
aminocyclopentene-3-carboxylates, followed by the stereoselective opening of the
isoxazoline ring (Scheme 1) [7].
Results and Discussion. – Our current aim was to synthesize highly functionalized
regio- and stereoisomers of F-containing five-membered cyclic b-amino acid deriva-
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tives from bicyclic b-lactam 4 through selective transformation of its C¼C bond by the
dipolar cycloaddition of a nitrile oxide, followed by reductive isoxazoline opening and
H/F exchange.
Accordingly, novel OH-containing, multifunctionalized b-aminocyclopentanecar-
boxylates were prepared by reductive ring opening of the isoxazoline skeleton of 9 and
10 [8] (Scheme 2). In contrast to our earlier experiments onMe-substituted compounds
(cf. Scheme 1) [7], the reductive isoxazoline opening of Et-substituted cis- and trans-
isoxazoline-fused derivatives 9 and 10 under similar experimental conditions, with
NaBH4 in the presence of NiCl2 in EtOH/THF, did not prove to be 100% stereo-
selective. Both transformations furnished two diastereoisomers, 11 (Fig. 1) and 12, or
13 and 14, in a ratio of 3 :1, the major products, 11 and 13, respectively, resulting fromH
attack on the isoxazoline from the same face of the carbamate (Scheme 2 ; for several
related transformations, see [3]). The products 11þ12 and 13þ14 were separated and
isolated by column chromatography on SiO2.
New multifunctionalized hydroxylated cispentacin analogs containing a longer
alkyl chain were next prepared by cycloaddition of the nitrile oxide formed from 2-
ethylbutyraldehyde oxime in the presence of N-chlorosuccinimide (NCS; Huisgens
conditions) to ethyl cis- and trans-2-aminocyclohexenecarboxylates, 15 and 18,
Scheme 2
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Scheme 1
respectively (Scheme 3). The cycloaddition to 15 gave isoxazoline-fused amino ester
regioisomers 16/17 in a ratio of 7.5 : 1 (Scheme 3), the major product containing the O-
atom of the isoxazoline skeleton farther from the carbamate group (for analogous
transformations, see [8a]). The products were separated by chromatography. Similarly
as with other nitrile oxides [8b], the cycloaddition to the trans counterpart 18
selectively afforded only cycloadduct 19 (Scheme 3).
Analogously to 9 and 10, the reductive ring openings of isoxazoline-fused cis- and
trans-amino esters 16 and 19, respectively, with NaBH4/NiCl2 each furnished two
products, 20 (Fig. 2 ; the H2O adduct of the compound)/21, or 22/23, respectively, in a
ratio of 2 : 1 and 3 :1, which were separated by column chromatography (Scheme 4).
Introduction of a F-atom in the skeleton of the major isomers of the synthesized
highly-functionalized cispentacin derivatives possessing a OH substituent was achieved
through H/F exchange with Deoxo-Fluor (¼ bis(2-methoxyethyl)aminosulfur tri-
fluoride) as reagent.
Fluorination of 7, 11, and 20 in dry toluene at 08 for 2 h afforded the corresponding
fluorinated compounds with inversion, 24a–24c, and the elimination products 25a–25c,
respectively (for analogous experimental results, see [6a] [6b] and ref. cit. therein;
Scheme 5), which were separated by column chromatography. No experimental
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Fig. 1. a)Molecular structure of compound 11. Only one of two similar molecules in the asymmetric unit
is presented. b)Ball-and-stick model of 11 showing inter- and intramolecular H-bonds. Thermal ellipsoids
have been drawn at 30% probability level, and the CH H-atoms are omitted for clarity.
conditions were found under which the large amounts of elimination products could be
avoided.
Under similar conditions, fluorination of the trans counterparts 8, 13, and 22
provided the required fluorinated products 26a and 26b, unfortunately again together
with large quantities of elimination products 27a–27c, respectively (Scheme 6).
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Scheme 3
Fig. 2. Molecular structure of compound 20 ·H2O. Thermal ellipsoids have been drawn at 30%
probability level, and the CH H-atoms are omitted for clarity.
To summarize, highly functionalized fluorinated b-aminocyclopentanecarboxylate
regio- and stereoisomers containing multiple stereogenic centers were synthesized
from b-aminocyclopentenecarboxylates through the 1,3-dipolar cycloaddition of nitrile
oxides and reductive ring opening of the isoxazoline skeleton, followed by H/F
exchange. These products may be regarded not only as fluorinated cispentacin
derivatives, but as precursors for the preparation of b-amino acid-modified peramivir
analogs.
We are grateful to the Hungarian Research Foundation (OTKA No. NK81371 and K100530) for
financial support.
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General. The chemicals were purchased from Aldrich. The solvents were used as received from the
supplier. M.p.:Kofler apparatus. NMR Spectra:Bruker DRX 400 spectrometer, chemical shifts, d, in ppm
rel. to TMS as internal standard, with CDCl3 as solvent. MS: FinniganMAT 95S spectrometer. Elemental
analyses: Perkin-Elmer CHNS-2400 Ser II elemental analyzer.
Synthesis of 2-Ethylbutyraldehyde Oxime (¼ (1E)-2-Ethyl-N-hydroxybutan-1-imine) . To a soln. of 2-
ethylbutyraldehyde (¼2-ethylbutanal; 50 mmol) in EtOH (50 ml), dry pyridine (150 mmol), and
NH2OH·HCl (50 mmol) were added, and the mixture was stirred under reflux for 7 h. The mixture was
then concentrated under reduced pressure, and the crude residue was purified by column chromatog-
raphy (CC) on SiO2 (hexane/AcOEt) to give (1E)-2-ethyl-N-hydroxybutan-1-imine.
General Procedure for the Synthesis of Isoxazoline-Fused b-Aminocyclopentanecarboxylates. To a
soln. of amino ester 15 or 18 (19.6 mmol) in THF (70 ml), (1E)-2-ethyl-N-hydroxybutan-1-imine
(118 mmol) , Et2NH (19.6 mmol) , and N-chlorosuccinimide (¼1-chloropyrrolidine-2,5-dione;
78.4 mmol) were added, and the mixture was stirred at r.t. for 48 h. The mixture was then diluted with
AcOEt (75 ml), washed with H2O (320 ml), dried (Na2SO4), and concentrated under reduced
pressure. The crude mixture was purified by CC (SiO2; hexane/AcOEt to give 16/17 and 19).
General Procedure for Isoxazoline Ring Opening. To a soln. of dihydroisoxazol 9, 10, 16, or 19
(1.46 mmol) in 10 ml of EtOH/THF 3 :1 (v/v), NiCl2 (2.92 mmol) and Boc2O (2.92 mmol) were added.
After stirring for 10 min, NaBH4 (2.92 mmol) was added in portions. The mixture was stirred at r.t. for
5 h, and the reaction was then quenched by the addition of H2O (5 ml). The mixture was filtered through
Celite pad, and the filtrate was concentrated under reduced pressure. The residue was diluted with
AcOEt (30 ml), washed with H2O (310 ml), dried (Na2SO4), and evaporated in vacuo. The products
11/12, 13/14, 20/21, and 22/23 were purified and separated by CC (SiO2; hexane/AcOEt).
General Procedure for the Synthesis of F-Containing b-Aminocyclopentanecarboxylates. To a soln. of
hydroxy compounds 7, 8, 11, 13, 20, or 22 (0.5 mmol) in dry toluene (10 ml),Deoxo-Fluor soln. (50% in
toluene, 0.6 mmol) was added at 08 under Ar. The mixture was stirred at 08 for 2 h, and the mixture was
then diluted with AcOEt, washed with sat. NaHCO3 soln. (310 ml), followed byH2O (210 ml), dried
(Na2SO4), and concentrated under reduced pressure. The crude residue was purified by CC (SiO2;
hexane/AcOEt)to furnish 24a–24c, 25a–25c, 26a and 26b, and 27a–27c.
Ethyl (1R*,2S*,3S*,4R*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}propyl)-4-hydroxycyclopentanecarboxylate (11). White solid. Yield: 57%. Rf (hexane/AcOEt)
0.24. M.p. 95–968. 1H-NMR (400 MHz, CDCl3): 0.95 (t, J¼7.36, Me); 1.30 (t, J¼7.2, Me); 1.45 (s, tBu);
1.49 (s, tBu); 1.94–2.16 (m, 2 CH2); 3.34–3.65 (m, HC(1)); 3.79–3.89 (m, HC(3)); 4.12–4.30 (m,
HC(2), CH, CH2O); 4.44–4.55 (m, HC(4)); 5.26–5.37 (br. s, NH); 5.61–5.72 (br. s, NH). 13C-NMR
(100 MHz, CDCl3): 10.9; 13.7; 27.9; 28.0; 28.4; 36.4; 43.8; 50.1; 50.3; 53.8; 60.3; 72.9; 79.3; 79.6; 155.2;
157.3; 174.9. ESI-MS: 431 ([Mþ1]þ ). Anal. calc. for C21H38N2O7: C 58.58, H 8.90, N 6.51; found: C 58.55,
H 8.92, N 6.49.
Ethyl (1R*,2S*,3S*,4R*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1R*)-1-{[(tert-butoxy)carbonyl]-
amino}propyl)-4-hydroxycyclopentanecarboxylate (12). White solid. Yield:18%. Rf (hexane/AcOEt
2 :1) 0.33. M.p. 125–1278. 1H-NMR (400 MHz, CDCl3): 2.97 (t, J¼7.2, Me); 1.28 (t, J¼7.1, Me); 1.43 (s,
tBu); 1.48 (s, tBu); 1.65–1.89 (m, CH2); 1.96–2.18 (m, CH2); 3.50–3.61 (m, HC(1)); 3.66–3.77 (m,
HC(3)); 4.06–4.27 (m, CH, HC(2); CH2O); 4.38–4.49 (m, HC(4)); 4.58–4.72 (br. s, 2 NH).
13C-NMR (100 MHz, CDCl3): 10.0; 13.8; 25.3; 27.9; 35.4; 45.6; 50.9; 51.9; 56.6; 60.2; 71.3; 78.9; 79.5;
154.4; 156.7; 174.1. ESI-MS: 431 ([Mþ1]þ ). Anal. calc. for C21H38N2O7: C 58.58, H 8.90, N 6.51; found: C
59.12, H 8.02, N 6.60.
Ethyl (1R*,2S*,3R*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}propyl)-3-hydroxycyclopentanecarboxylate (13). White solid. Yield: 64%. Rf (hexane/AcOEt)
0.57. M.p. 216–2178. 1H-NMR (400 MHz, CDCl3): 0.96 (t, J¼7.4, Me); 1.25–1.33 (m, Me); 1.44 (s, tBu);
1.49 (s, tBu); 1.76–2.38 (m, 2 CH2); 2.47–2.62 (m, HC(1)); 2.76–2.96 (m, HC(4)); 3.10–3.19 (m,
HC(2)); 3.68–3.80 (m, CH); 4.10–4.24 (m, CH2O); 4.28–4.38 (br. s, NH); 4.42–4.47 (m, HC(3));
5.01–5.25 (br. s, NH). 13C-NMR (100 MHz, CDCl3): 10.3; 11.1; 27.0; 28.1; 32.4; 33.2; 45.2; 52.3; 50.8; 54.1;
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58.8; 72.1; 77.0; 154.5; 156.5; 175.4. ESI-MS: 431 ([Mþ1]þ ). Anal. calc. for C21H38N2O7: C 58.58, H 8.90,
N 6.51; found: C 58.57, H 8.91, N 6.49.
Ethyl (1R*,2S*,3R*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1R*)-1-{[(tert-butoxy)carbonyl]-
amino}propyl)-3-hydroxycyclopentanecarboxylate (14). Brownish oil. Yield: 21%. Rf (hexane/AcOEt)
0.35. 1H-NMR (400 MHz, CDCl3): 0.96 (t, J ¼ 7.6, Me); 1.25–1.33 (m, Me); 1.45 (s, tBu); 1.50 (s, tBu);
1.81–2.15 (m, 2 CH2); 2.24–2.36 (m, HC(4)); 2.74–2.86 (m, HC(1)); 3.69–3.82 (m, CH); 4.09–4.26
(m, HC(2), HC(3), CH2O); 4.29–4.39 (br. s, NH); 5.03–5.20 (br. s, NH). 13C-NMR (100 MHz,
CDCl3): 10.0; 11.0; 27.9; 28.0; 31.1; 35.5; 45.2; 51.7; 51.1; 56.5; 60.1; 71.6; 78.1; 154.4; 155.5; 174.6. ESI-MS:
453 ([MþNa]þ ). Anal. calc. for C21H38N2O7: C 58.58, H 8.90, N 6.51; found: C 58.57, H 8.98, N 6.50.
Ethyl (3aR*,4S*,5R*,6aR*)-4-{[(tert-Butoxy)carbonyl]amino}-3-(1-ethylpropyl)-4,5,6,6a-tetrahy-
dro-3aH-cyclopenta[d] [1,2]oxazole-5-carboxylate (16). Brownish oil. Yield: 45%. Rf (hexane/AcOEt)
0.72. 1H-NMR (400 MHz, CDCl3): 0.90–1.00 (m, 2 Me); 1.30 (t, J¼7.1, Me); 1.47 (s, tBu); 1.54–1.84 (m,
2 CH2); 2.25–2.41 (m, CH2); 2.46–2.55 (m, HC(5)); 2.94–3.07 (m, HC(3a)); 3.64–3.75 (m, CH);
4.16–4.31 (m, CH2O, HC(4)); 5.06–5.20 (m, HC(6a), NH). 13C-NMR (100 MHz, CDCl3): 11.4; 12.5;
14.5; 24.4; 25.9; 28.6; 31.6; 36.9; 41.0; 45.6; 52.1; 57.1; 61.6; 62.9; 83.7; 155.4; 160.8. ESI-MS: 369 ([Mþ1]þ ).
Anal. calc. for C19H32N2O5: C 61.93, H 8.75, N 7.60; found: C 61.92, H 8.76, N 6.7.58.
Ethyl (3aR*,5S*,6S*,6aR*)-6-{[(tert-Butoxy)carbonyl]amino}-3-(1-ethylpropyl)-4,5,6,6a-tetrahy-
dro-3aH-cyclopenta[d] [1,2]oxazole-5-carboxylate (17). Yellowish oil. Yield: 6%. Rf (hexane/AcOEt)
0.52. 1H-NMR (400 MHz, CDCl3): 1.21–1.33 (m, 3 Me); 1.46 (s, tBu); 1.51–2.20 (m, 2 CH2); 2.32–2.46
(m, CH2); 2.93–3.07 (m, HC(5)); 3.44–3.54 (m, HC(3a)); 4.01–4.24 (m, CH, CH2O); 4.28–4.40 (m,
HC(6)); 4.87–4.92 (m, HC(6a)); 5.64–5.80 (br. s, NH). 13C-NMR (100 MHz, CDCl3): 10.5; 11.2; 14.5;
23.9; 26.2; 30.0; 31.4; 35.9; 42.1; 44.9; 52.2; 56.9; 59.6; 62.9; 85.0; 155.4; 161.4. ESI-MS: 369 ([Mþ1]þ ).
Anal. calc. for C19H32N2O5: C 61.93, H 8.75, N 7.60; found: C 61.91, H 8.76, N 7.61.
Ethyl (3aS*,5R*,6S*,6aR*)-6-{[(tert-butoxy)carbonyl]amino}-3-(1-ethylpropyl)-4,5,6,6a-tetrahydro-
3aH-cyclopenta[d] [1,2]oxazole-5-carboxylate (19). White solid. Yield: 50%. Rf (hexane/AcOEt) 0.38.
M.p. 95–968. 1H-NMR (400 MHz, CDCl3): 0.89–1.00 (m, 2 Me); 1.29 (t, J¼7.1, Me); 1.46 (s, tBu); 1.55–
1.74 (m, 2 CH2); 1.97–2.04 (m, 1 H of CH2); 2.14–2.31 (m, 1 H of CH2, HC(5)); 2.38–2.49 (m,
HC(3a)); 3.62–3.73 (m, CH); 4.09–4.34 (m, HC(6), CH2O); 4.85–4.91 (m, HC(6a)); 5.19–5.26 (br.
s, NH). 13C-NMR (100 MHz, CDCl3): 10.5; 11.6; 13.6; 23.6; 25.3; 27.8; 29.9; 39.8; 46.4; 50.9; 59.5; 60.6;
79.0; 82.5; 154.6; 162.4; 172.2. ESI-MS: 369 ([Mþ1]þ ). Anal. calc. for C19H32N2O5: C 61.93, H 8.75, N
7.60; found: C 61.95, H 8.74, N 7.59.
Ethyl (1R*,2S*,3S*,4R*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}-2-ethylbutyl)-4-hydroxycyclopentanecarboxylate (20). White solid. Yield: 53%. Rf (hexane/
AcOEt) 0.26. M.p. 99–1008. 1H-NMR (400 MHz, CDCl3): 0.80–0.93 (m, 2 Me); 1.24–1.67 (m, 2 tBu,
CH2); 1.97–2.21 (m, 1 H of CH2, HC(1), HC(3)); 3.31–3.40 (m, CH); 3.77–3.89 (m, CH); 4.12–4.28
(m, HC(2), CH2O); 4.40–4.52 (m, HC(4)); 5.28–5.38 (br. s, NH); 5.80–5.90 (br. s, NH). 13C-NMR
(100 MHz, CDCl3): 9.6; 9.9; 13.7; 20.8; 21.4; 27.9; 28.0; 36.5; 43.0; 43.66; 50.1; 50.2; 50.4; 60.4; 73.4; 79.2;
79.5; 155.1; 157.2; 175.1. ESI-MS: 495 ([MþNa]þ ). Anal. calc. for C24H44N2O7: C 60.99, H 9.38, N 5.93;
found: C 61.01, H, 9.39, N, 5.94.
Ethyl (1R*,2S*,3S*,4R*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1R*)-1-{[(tert-butoxy)carbonyl]-
amino}-2-ethylbutyl)-4-hydroxycyclopentanecarboxylate (21). White solid. Yield: 27%. Rf (hexane/
AcOEt) 0.53. M.p. 197–1988. 1H-NMR (400 MHz, CDCl3): 0.90–1.03 (m, 2 Me); 1.08–1.24 (m, 1 H of
CH2); 1.29 (t, J¼7.2, Me); 1.38–1.59 (m, 2 tBu, CH2); 1.83–1.95 (m, 1 H of CH2); 1.97–2.21 (m, CH2);
3.51–3.65 (m, HC(1)); 3.89–3.99 (m, CH); 4.02–4.73 (m, CH, CH2O, HC(2), HC(3), HC(4)).
13C-NMR (100 MHz, CDCl3): 11.4; 11.5; 14.0; 21.2; 22.7; 27.9; 27.94; 35.0; 41.1; 46.1; 50.6; 51.9; 54.2; 50.2;
71.7; 78.9; 79.8; 154.1; 157.2; 174.0. ESI-MS: 495 ([MþNa]þ ). Anal. calc. for: C24H44N2O7: C 60.99, H
9.38, N 5.93; found: C 60.98, H 9.40, N 5.91.
Ethyl (1R*,2S*,3R*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}-2-ethylbutyl)-3-hydroxycyclopentanecarboxylate (22). Yellowish oil. Yield: 58%. Rf (hexane/
AcOEt) 0.47. 1H-NMR (400 MHz, CDCl3): 0.90–1.01 (m, 2 Me); 1.09–1.34 (m, Me, 2 CH2); 1.46 (s,
2 tBu); 1.92–2.30 (m, CH2, HC(1)); 2.76–2.88 (m, HC(4)); 2.94–3.02 (m, CH); 3.92–4.03 (m, CH);
4.06–4.31 (m, HC(2), HC(3), CH2O); 4.35–4.44 (br. s, NH); 5.07–5.19 (br. s, NH). 13C-NMR
(100 MHz, CDCl3): 11.0; 12.0; 14.3; 21.0; 24.3; 26.2; 27.0; 28.4; 44.3; 45.4; 48.0; 51.6; 58.8; 63.0; 73.8; 80.0;
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127.0; 142.0; 153.7; 158.1. ESI-MS: 474 ([Mþ1]þ ). Anal. calc. for C24H44N2O7: C 60.99, H 9.38, N 5.93;
found: C 60.97, H 9.39, N 5.94.
Ethyl (1R*,2S*,3R*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1R*)-1-{[(tert-butoxy)carbonyl]-
amino}-2-ethylbutyl)-3-hydroxycyclopentanecarboxylate (23). White solid. Yield: 20%. Rf (hexane/
AcOEt) 0.35. M.p. 137–1388. 1H-NMR (400 MHz, CDCl3): 0.89–1.00 (m, 2 Me); 1.29 (t, J¼7.1, Me);
1.40–1.72 (m, 2 tBu, 4 CH2); 1.96–2.52 (m, CH2, HC(1), HC(4), CH); 3.60–3.76 (m, CH); 4.07–4.42
(m, HC(2), CH2O, HC(3)); 4.84–4.93 (br. s, NH); 5.16–5.30 (br. s, NH). 13C-NMR (100 MHz,
CDCl3): 11.5; 11.9; 13.7; 21.2; 22.6; 25.2; 27.9; 27.9; 44.3; 44.7; 46.3; 50.9; 58.8; 60.3; 74.2; 79.1; 126.9;
142.0; 154.9; 156.3. ESI-MS: 474 ([Mþ1]þ ). Anal. calc. for C24H44N2O7: C 60.99, H 9.38, N 5.93; found: C
61.01, H 9.36, N 5.92.
Ethyl (1R*,2R*,3S*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}ethyl)-4-fluorocyclopentanecarboxylate (24a). White solid. Yield: 24%. Rf (hexane/AcOEt)
0.56. M.p. 114–1158. 1H-NMR (400 MHz, CDCl3): 1.23 (d, J¼6.9, Me); 1.27–1.33 (m, Me); 1.43–1.49
(m, 2 tBu); 2.11–2.42 (m, CH2, HC(1)); 3.00–3.08 (m, HC(3)); 4.41–4.28 (m, NH, CH, CH2O); 4.83–
5.09 (m, HC(4), HC(2)); 5.58–5.67 (br. s, NH). 13C-NMR (100 MHz, CDCl3): 14.5; 19.6; 28.8; 34.8;
34.9; 45.2; 46.1; 52.2; 55.9; 56.1; 61.3; 79.1; 79.8; 95.9; 152.8; 173.5. ESI-MS: 419 ([Mþ1]þ ). Anal. calc.
for: C20H35FN2O6: C 57.40, H 8.43, N 6.69; found: C 57.43, H 8.42, N 5.67.
Ethyl (1R*,2R*)-2-{[(tert-butoxy)carbonyl]amino}-3-((1S*)-1-{[(tert-butoxy)carbonyl]amino}-
ethyl)cyclopent-3-ene-1-carboxylate (25a). White solid. Yield: 45%. Rf (hexane/AcOEt) 0.52. M.p. 83–
848. 1H-NMR (400 MHz, CDCl3): 1.26–1.33 (m, 2 Me); 1.42–1.50 (m, 2 Me3C); 2.41–2.52 (m, 1 H of
CH2); 2.75–2.86 (m, 1 H of CH2); 3.36–3.45 (m, HC(1)); 4.12–4.22 (m, CH2O); 4.34 (br. s, NH); 4.70–
5.08 (m, NH, CH, HC(2)); 5.65 (s, HC(4)). 13C-NMR (100 MHz, CDCl3): 14.6; 21.2; 28.7; 28.8; 33.3;
45.7; 47.7; 57.4; 61.0; 79.9; 121.4; 126.2; 155.5; 158.5; 172.9. ESI-MS: 399 ([Mþ1]þ ). Anal. calc. for
C20H34N2O6: C 60.28, H 8.60, N 7.03; found: C 60.26, H 8.61, N 7.04.
Ethyl (1R*,2R*,3S*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}propyl)-4-fluorocyclopentanecarboxylate (24b). White solid. Yield: 30%. Rf (hexane/AcOEt)
0.74. M.p. 103–1048. 1H-NMR (400 MHz, CDCl3): 0.97 (t, J¼7.3, Me); 1.26–1.33 (m, Me); 1.44 1.50
(m, 2 tBu); 1.57–1.67 (m, CH2); 2.09–2.45 (m, CH2, HC(1)); 2.97–3.06 (m, HC(3)); 3.86 (br. s, NH);
4.03–4.28 (m, CH2O, HC(2)); 4.80–5.03 (m, CH, HC(4)); 5.66–5.76 (br. s, NH). 13C-NMR (100 MHz,
CDCl3): 10.5; 13.6; 26.4; 27.9; 34.1; 44.5; 50.9; 51.3; 54.0; 60.5; 78.8; 79.3; 94.5; 95.9; 155.0; 155.9; 173.3.
ESI-MS: 434 ([Mþ1]þ ). Anal. calc. for C21H37FN2O6: C 58.31, H 8.62, N 6.48; found: C 58.29, H 8.63, N
6.49.
Ethyl (1R*,2R*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1S*)-1-{[(tert-butoxy)carbonyl]amino}pro-
pyl)cyclopent-3-ene-1-carboxylate (25b). Brownish oil. Yield: 43%. Rf (hexane/AcOEt) 0.67. 1H-NMR
(400 MHz, CDCl3): 0.91 (t, J¼7.5, Me); 1.29 (t, J¼7.2, Me); 1.42–1.50 (m, tBu); 1.62–1.77 (m, CH2);
2.34–2.53 (m, 1 H of CH2); 2.74–2.90 (m, 1 H of CH2); 3.30–3.45 (m, HC(1)); 4.09–4.28 (m, CH,
CH2O); 4.78–5.05 (m, 2 NH, HC(2)); 5.65 (s, HC(4)). 13C-NMR (100 MHz, CDCl3): 9.6; 13.8; 26.6;
27.9; 27.9; 32.5; 46.7; 56.6; 60.2; 79.1; 112.5; 115.4; 117.2; 126.4; 154.8; 171.3; 172.2. ESI-MS: 414 ([Mþ1]þ ).
Anal. calc. for C21H36N2O6: C 61.14, H 8.80, N 6.79; found: C 61.13, H 8.82, N 6.80.
Ethyl (1R*,2R*,3S*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}-2-ethylbutyl)-4-fluorocyclopentanecarboxylate (24c). White solid. Yield: 28%. Rf (hexane/
AcOEt) 0.75. M.p. 115–1168. 1H-NMR (400 MHz, CDCl3): 0.83–0.95 (m, 2 Me); 1.17–1.37 (m, Me,
CH2); 1.40–1.52 (m, 2 tBu, CH2); 2.10–2.38 (m, CH2, CH); 2.46–2.62 (m, HC(1)); 2.98–3.09 (m,
HC(3)); 3.79–3.90 (m, CH); 4.03–4.29 (m, HC(2), CH2O); 4.82 (br. s, NH); 4.91–5.06 (m, HC(4));
5.68–5.79 (br. s, NH). 13C-NMR (100 MHz, CDCl3): 9.5; 10.3; 13.6; 20.8; 21.4; 27.9; 34.0; 41.9; 44.7; 51.1;
51.2; 51.5; 60.5; 78.7; 79.2; 95.3; 96.7; 154.9; 156.0; 173.4. ESI-MS: 475 ([Mþ1]þ ). Anal. calc. for
C24H43FN2O6: C 60.74, H 9.13, N 5.90; found: C 60.73, H 9.12, N 5.92.
Ethyl (1R*,2R*)-2-{[(tert-Butoxy)carbonyl]amino}-3-((1S*)-1-{[(tert-butoxy)carbonyl]amino}-2-
ethylbutyl)cyclopent-3-ene-1-carboxylate (25c). White solid. Yield: 27%. Rf (hexane/AcOEt) 0.61. M.p.
94–958. 1H-NMR (400 MHz, CDCl3): 0.84–1.11 (m, 2 Me, CH2); 1.17–1.36 (m, Me, CH2); 1.39–1.53 (m,
2 tBu); 2.40–2.53 (m, 1 H of CH2); 2.76–2.89 (m, 1 H of CH2); 3.36–3.47 (m, CH); 4.09–4.25 (m,
CH2O); 436 (br. s, NH); 4.62–5.07 (m, CH, NH, HC(2)); 5.63–5.65 (m, HC(4)). 13C-NMR (100 MHz,
CDCl3): 11.2; 12.2; 13.8; 21.1; 22.2; 27.8; 27.9; 32.4; 42.4; 46.7; 50.3; 56.5; 60.1; 78.8; 78.9; 126.5; 143.1;
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154.6; 155.2; 172.1. ESI-MS: 455 ([Mþ1]þ ). Anal. calc. for C24H42N2O6: C 63.41, H 9.31, N 6.16; found: C
63.39, H 9.32, N 6.17.
Ethyl (1R*,2S*,3S*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}ethyl)-3-fluorocyclopentanecarboxylate (26a). White solid. Yield: 26%. Rf (hexane/AcOEt)
0.51. M.p. 104–1058. 1H-NMR (400 MHz, CDCl3): 1.17–1.23 (m, Me); 1.29 (t, J¼7.2, Me); 1.44–1.49 (m,
2 tBu); 2.09–2.24 (m, 1 H of CH2); 2.27–2.58 (m, 1 H of CH2, HC(1)); 2.69–2.94 (m, HC(4)); 3.69–
3.89 (m, CH); 4.09–4.25 (m, CH2O, HC(2)); 4.26–4.43 (br. s, NH); 4.65–5.00 (m, NH, HC(3)).
13C-NMR (100 MHz, CDCl3): 13.7; 15.5; 27.9; 33.5; 36.6; 46.5; 48.1; 50.8; 51.5; 51.7; 60.6; 79.2; 103.6;
105.0; 154.8; 172.6. ESI-MS: 419 ([Mþ1]þ ). Anal. calc. for C20H35FN2O6: C 57.40, H 8.43, N 6.69; found:
C 57.41, H 8.41, N 6.70.
Ethyl (1R*,4R*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1S*)-1-{[(tert-butoxy)carbonyl]amino}-
ethyl)cyclopent-2-ene-1-carboxylate (27a). White solid. Yield: 48%. Rf (hexane/AcOEt) 0.47. M.p.
129–1308. 1H-NMR (400 MHz, CDCl3): 1.18–1.3 (m, Me); 1.26–1.33 (m, Me); 1.45–1.48 (m, 2 tBu);
2.29–2.49 (m, HC(1)); 2.57–2.79 (m, CH2); 2.81–2.91 (m, HC(4)); 3.70–3.87 (m, NH); 4.15–4.25 (m,
CH2O, CH); 4.92–5.01 (m, NH); 5.45–5.47 (m, HC(3)). 13C-NMR (100 MHz, CDCl3): 13.7; 19.4; 27.9;
36.77; 44.9; 46.7; 46.6; 50.7; 60.4; 78.0; 79.2; 124.7; 148.3; 154.7; 167.8. ESI-MS: 399 ([Mþ1]þ ). Anal.
calc. for C20H34N2O6: C 60.28, H 8.60, N 7.03; found: C 60.30, H 8.59, N 7.02.
Ethyl (1R*,2S*,3S*,4S*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1S*)-1-{[(tert-butoxy)carbonyl]-
amino}propyl)-3-fluorocyclopentanecarboxylate (26b). Brownish oil. Yield: 15%. Rf (hexane/AcOEt)
0.57. 1H-NMR (400 MHz, CDCl3): 0.89–1.02 (m, Me); 1.25–1.33 (m, Me); 1.44–1.50 (m, 2 tBu); 1.64–
1.80 (m, CH2); 2.23–3.06 (m, CH2, HC(1), CH); 3.49–3.72 (m, HC(4)); 4.14–4.25 (m, CH2O); 4.29–
4.54 (m, HC(2)); 4.57–4.82 (m, HC(3)); 4.97 (br. s, NH); 5.13 (br. s, NH). 13C-NMR (100 MHz,
CDCl3): 9.9; 13.7; 22.7; 27.9; 36.8; 47.9; 49.7; 52.9; 53.7; 57.3; 57.5; 60.5; 79.1; 103.8; 105.2; 154.3; 155.8.
ESI-MS: 433 ([Mþ1]þ ). Anal. calc. for C21H37FN2O6: C 58.31, H 8.62, N 6.48; found: C 58.30, H 8.61, N
6.50.
Ethyl (1R*,4R*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1S*)-1-{[(tert-butoxy)carbonyl]amino}pro-
pyl)cyclopent-2-ene-1-carboxylate (27b). White solid. Yield: 39%. Rf (hexane/AcOEt) 0.48. M.p. 121–
1228. 1H-NMR (400 MHz, CDCl3): 0.88–1.01 (m, Me); 1.24–1.33 (m, Me); 1.47 (s, 2 tBu); 1.61–1.90 (m,
CH2); 2.09–2.35 (m, 1 H of CH2); 2.53–2.75 (m, 1 H of CH2); 2.77–2.92 (m, HC(1)); 4.07–4.25 (m,
HC(4), CH2O); 4.47 (br. s, NH); 4.56–4.87 (m, CH); 4.93–5.05 (m, NH); 5.45–5.47 (m, HC(3)).
13C-NMR (100 MHz, CDCl3): 9.8; 13.7; 22.6; 26.1; 27.9; 50.6; 51.5; 57.3; 60.5; 79.0; 103.8; 105.2; 124.6;
154.6; 155.8; 172.7. ESI-MS: 413 ([Mþ1]þ ). Anal. calc. for C21H36N2O6: C 61.14, H 8.80, N 6.79; found: C
61.15, H 8.78, N 6.80.
Ethyl (1R*,4R*)-2-{[(tert-Butoxy)carbonyl]amino}-4-((1S*)-1-{[(tert-butoxy)carbonyl]amino}-2-
ethylbutyl)cyclopent-2-ene-1-carboxylate (27c). Yellowish oil. Yield: 58%. Rf (hexane/AcOEt) 0.48.
1H-NMR (400 MHz, CDCl3): 0.85–1.17 (m, 2 Me, CH2); 1.23–1.39 (m, Me, CH2); 1.46 (s, 2 tBu); 1.58–
1.68 (m, CH2); 2.41–2.90 (m, CH, HC(1), CH); 3.51–3.61 (m, HC(4)); 4.07–4.22 (m, CH2O); 4.37
(br. s, NH); 4.49 (br. s, NH); 5.63–5.64 (m, HC(3)). 13C-NMR (100 MHz, CDCl3): 10.8; 11.2; 13.7; 21.5;
22.6; 27.8; 27.9; 34.4; 43.1; 50.2; 52.0; 57.11; 60.4; 78.5; 79.1; 103.2; 105.5; 153.9; 155.8; 171.7. ESI-MS: 455
([Mþ1]þ ). Anal. calc. for C24H42N2O6: C 63.41, H 9.31, N 6.16; found: C 63.44, H 9.30, N 6.14.
X-Rray Crystallographic Studies. Crystallographic data for the compounds 11 and 20 were collected
with Agilent Supernova diffractometer equipped with Atlas area detector using CuKa radiation (l¼
1.54184 ). Empirical absorption correction, using spherical harmonics implemented in SCALE3
ABSPACK scaling algorithm, was applied for both compounds with CrysAlisPro program package [9].
The structures were solved by direct methods using SIR97 [10] program, and full-matrix, least-squares
refinements on F2 were performed using the SHELXL-97 [11] program. Molecular structure figures were
drawn with Diamond3 program [12]. Selected crystallographic data collected in CCDC-902350 and
-902351 contain the supplementary crystallographic data for 11 and 20. These data can be obtained free of
charge via ttp://www.ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge Crystallographic Data
Centre, 12 Union Road, Cambridge CB21EZ, UK; fax: (þ44)1223-336-033; or e-mail: deposit@ccdc.
cam.ac.uk.
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